Covalon Technologies Ltd. · TSXV:COV
Covalon Technologies — Shareholder Meeting (March 2023)
27 slides from Covalon Technologies's shareholder meeting presentation, Mar 8, 2023
Slide 1: 2022 Annual Shareholders Meeting
TSX-V: COV OTCQX: CVALF 2022 Annual Shareholders Meeting March 8th 2023 Brian Pedlar, CEO www.covalon.com helping the most vulnerable patients have a better chance at healing 1
Slide 2: Management Presentation
Brian Pedlar Management Presentation President & CEO B.Sc., CPA, CA 2 2
Slide 3: Forward-Looking Statements and Non-GAAP Financial Information
Forward-Looking Statements and Non-GAAP Financial Information Certain statements included in this presentation may be considered forward-looking statements. These forward-looking statements are often, but not always, identified by the use of words such as “seek”, “anticipate”, “plan”, “estimate”, “e
Slide 4: We aren't just another medical device company…
TSX-V: COV We aren’t just OTCQX: CVALF another medical device company… Covalon is a patient-driven medical device company, built on the relentless pursuit to help the most vulnerable patients have a better chance at healing. Through a strong portfolio of patented technologies and solutions for advan
Slide 5: Capitalization Table
TSX-V: COV OTCQX: CVALF ~55% Insider ownership Capitalization Table (in Canadian $) $14mm Share Price (March 7, 2023) ($/share) $2.15 Basic Shares (mm) 24.9 FD ITM Shares (mm) 28.9 Cash FD ITM Market Cap ($ mm) $62.2 Less: Cash (Dec 31, 2022) ($ mm) ($14.1) Plus: Debt Plus: Minority Interest ($ mm)
Slide 6: Balance Sheet with Significant Cash and No Debt
Balance Sheet with Significant Cash and No Debt Key Takeaways Sept. 30, 2022 Dec. 31, 2022 • We ended both Q1 2023 and fiscal 2022 with $14M Cash $14.1M $14.1M cash on the balance sheet Current Assets $27.2M $26.7M Total Assets $30.4M $30.0M • Current assets consists of cash, accounts receivable, in
Slide 7: Annual Revenue Profile and Margins
Annual Revenue Profile and Margins Key Takeaways • COVID recovery underway in the U.S. with ROW markets slower to recover • Forecasting revenue growth for 2023 • Decline in International revenue due to exiting U.K. market • Gross margins are heavily influenced by inventory provision and product mix
Slide 8: Quarterly Revenue Growth Last 4 Quarters
Quarterly Revenue Growth Last 4 Quarters Key Takeaways • Strong revenue growth over the past 4 quarters • Forecasting revenue growth for 2023 • United States revenue growth tracking to plan • Middle East revenue continuing to return to expected levels, but still “lumpy” quarter to quarter • Rest of
Slide 9: Fiscal 2023: Strong Path to Financial Growth
Fiscal 2023: Strong Path to Financial Growth Investing in Sales and Marketing initiatives to drive aggressive 2025 Targets: growth in our US Hospital Market • Currently have 70 major hospital customers (> 300 beds) 400 • 3 strong infection prevention products Major Hospitals 6 of the Top 10 Pediatri
Slide 10: Covalon is focused on becoming a leading provider of compassionate care solutions
Covalon is focused on becoming a leading provider of compassionate care solutions that help patients heal faster and live better. 10
Slide 11: Our Mission
Our Mission Provide innovative and cost-effective healthcare solutions that reduce pain, prevent infection, and promote healing. 11
Slide 12: Helping Healthcare Providers Improve Patient Outcomes
Helping Healthcare Providers Improve Patient Outcomes The top priority of every healthcare worker is to provide the safest and best possible patient experience. Covalon’s priority is to help healthcare workers do that. Healthcare workers are stretched thin, but it doesn’t mean that care should be co
Slide 13: Uninsured Hospital-Acquired Infections have increased as much as 63% in ICUs
Uninsured Hospital-Acquired Infections have increased as much as 63% in Intensive Care Units1 1 Weiner-Lastinger, L., Pattabiraman, V., Konnor, R., Patel, P., Wong, E., Xu, S., Dudeck, M. (2022). The impact of coronavirus disease 2019 (COVID-19) on healthcare-associated infections in 2020: A summary
Slide 14: Current Standard of Care Products Are Ineffective
Current “Standard of Care” Products used to combat vascular access and surgical site infections (SSIs) in hospitals in the United States are ineffective1 1 Klevens, R. Monina; Edwards, Jonathan R.; Richards, Chesley L.; Horan, Teresa C.; Gaynes, Robert P; Pollock, Daniel A.; Cardo, Denise M. (2007).
Slide 15: 70% of Hospital-Acquired Infections Are Preventable
70% of Hospital-Acquired Infections Are Preventable $28 Billion 100,000 Treatment Cost1 Annual Deaths1 1.7 Million Annual US Hospital-Acquired Infections1 30% 70% It’s time to give frontline care Preventable Infections providers the right technology 1Klevens, R. Monina; Edwards, Jonathan R.; Richard
Slide 16: Clinicians and Patients are demanding Better, Safer Products
Clinicians and Patients are demanding Better, Safer Products … A Better Standard of Care 16
Slide 17: Many Prestigious Hospitals Choose Covalon
Many Prestigious Hospitals Choose Covalon Some of our Children’s Hospital Customers including 6 of the top 10 in the United States: Some of our Acute Care Hospital Customers in the United States: 17
Slide 18: Strong Distribution Channels
Strong Distribution Channels 2023 Revenue Breakdown > 70 Major Hospitals Direct Sales (> 300 Beds) 6 of 10 Strong Clinical Evidence Top 10 Children’s Hospitals 63% Long-term Care United States & Home Healthcare Distribution Partners 20 International Countries 37% Distributors ~20 International Distr
Slide 19: Our Patented FDA Cleared Product Solutions
Our Patented FDA Cleared Product Solutions Focus On Infection Prevention • Vascular Access Blood Stream Infections (“BSIs”) • Surgical Site Infections (“SSIs”) • Medical Device-related Infections Advanced Wound Healing • Diabetic chronic wounds • Surgical wounds • Traumatic non-healing wounds • Seri
Slide 20: Better Vascular Access Infection Prevention Solutions
Better Vascular Access Infection Prevention Solutions 25% Antimicrobial Catheter Coating 20
Slide 21: Better Surgical Site Infection Prevention Solutions
Better Surgical Site Infection Prevention Solutions 2121
Slide 22: Protecting patients from the inside out
Protecting patients from the inside out We work with some of the largest Medical Device Organizations to incorporate our infection prevention technologies into their well-known devices, helping clinicians to better protect patients from the inside out. Our Medical Coatings Save Lives 22 22
Slide 23: ColActive Plus®
ColActive Plus® For millions of Closes Complex Wounds patients, 6.7M complex Americans are living with a chronic, wounds are non-healing ulcer debilitating. 25% Of people living with Diabetes will experience a diabetic foot ulcer 1 in 4 Families has a family member with a chronic wound $50B The annu
Slide 24: Covalon Delivers
Selected Partners & Distributors Covalon Delivers Regulatory Pathway Expertise Our R&D, Quality, and Regulatory expertise is recognized and sought by global ISO13485: 2016, MDSAP and FDA QSR certified healthcare companies worldwide. Award Winning Products 24
Slide 25: Board of Directors
Board of Directors Abe Schwartz Amir Boloor Samantha Nutt Martin Goldfarb Joseph Cordiano Ronald E. Smith Brian Pedlar 25
Slide 26: Covalon Has a Strong Growth Platform
Covalon Has a Strong WHY INVEST Growth Platform IN COVALON Financially Strong Core Innovative Product Solutions Massive Growth Potential Business backed by Strong IP Significant cash; no debt Solid clinical evidence backing $8.9 billion infections and chronic Above-market revenue growth patented pro
Slide 27: www.covalon.com
covalon TECHNOLOGIES LTD.
Covalon Technologies — Shareholder Meeting (March 2023) on 6ix